Affimed Appoints Dr. Joerg Windisch as Chief Operating Officer and Adds Dr. Bernhard Ehmer to Supervisory Board

Press Release - January 21, 2016

Download Press Release

Heidelberg, Germany, January 21, 2016 -­ Affimed N.V. (Nasdaq: AFMD), a clinical stage biopharmaceutical  company  focused  on  discovering  and  developing  highly  targeted  cancer immunotherapies, today announced the appointment of Dr. Joerg Windisch to the position of Chief Operating Officer. As COO, Dr. Windisch will provide his broad expertise in pharmaceutical regulatory affairs, quality control and project management to support the Company’s expanding clinical pipeline. The Company also announced the addition of Dr.  Bernhard  Ehmer  to  its  Supervisory  Board.  Dr.  Ehmer  brings  an  extensive  clinical  development track record in biopharmaceuticals from both sides of the Atlantic. These appointments were approved by Affimed’s shareholders at the Extraordinary Shareholder Meeting held in Amsterdam today.

“Affimed continues to build a team that has the capabilities to realize the potential of our clinical programs and that will help us advance those programs toward commercialization,” said  Dr.  Adi  Hoess,  CEO  of  Affimed.  “We  will  greatly  benefit  from  Joerg’s  operational  leadership and Bernhard’s support as a key advisor as we move towards the next stage of corporate and clinical development.”

Dr.  Windisch  joins  Affimed  after  spending  20  years  at  Sandoz  Biopharmaceuticals  (a  Novartis company), most recently serving as Chief Science Officer. He joined Novartis in 1996 in the biologics unit of Sandoz, where he played a leading role in the development of  Somatropin  (Omnitrope®),  the  first  ever  biosimilar  medicine,  as  well  as  of  Sandoz’  Epoetinalfa (Binocrit®) and Filgrastim (Zarzio®) products. Over the course of 15 years he built an international technical development organization for biologics and for five years Dr.  Windisch  also  led  the  joint  biologics  technical  development  and  manufacturing  organization for Novartis Pharma and Sandoz. He was involved in the development and manufacturing of about 20 biologics, six of which are currently marketed. Dr. Windisch was educated in Austria, Germany and the U.S. and received his Ph.D. in Biochemistry and Molecular Biology from the University of Innsbruck. Dr. Ehmer has been Chairman of the Management Board of Biotest AG since January 2015. Prior to this, he worked for the Imclone Group, a wholly-­owned subsidiary of Eli Lilly, as  President  of  Imclone  Systems  Corporation  in  the  United  States  and  as  Managing Director  in  Germany.  In  2007/2008  he  was  CEO  of  Fresenius  Biotech,  Germany  and  before this, Dr. Ehmer headed the Business Area Oncology of Merck KGaA, Darmstadt and served as Head of Global Clinical Operations at Merck. Between 1986 and 1998 he held  various  functions  at  Boehringer  Mannheim  in  Germany,  Italy  and  Singapore.  Dr.  Ehmer holds a degree in medicine and worked in the Department of Internal Medicine at the Academic Teaching Hospital of the University of Heidelberg.

About Affimed N.V.

Affimed (Nasdaq: AFMD) is a clinical-stage biopharmaceutical company focused on discovering and developing highly targeted cancer immunotherapies. Affimed’s product candidates are being developed in the field of immuno-oncology, which represents an innovative approach to cancer treatment that seeks to harness the body’s own immune defenses to fight tumor cells. The most potent cells of the human defense arsenal are types of white blood cells called natural killer cells, or NK-cells, and T-cells. Affimed’s proprietary, next-generation bispecific antibodies, called TandAbs for their tandem antibody structure, are designed to direct and establish a bridge between either NK-cells or T-cells and cancer cells, triggering a signal cascade that leads to the destruction of cancer cells. Affimed has focused its research and development efforts on three proprietary TandAb programs for which it retains global commercial rights. For more information, please visit

Affimed Forward-Looking Statements

This press release contains forward-looking statements. All statements other than statements of historical fact are forward-looking statements, which are often indicated by terms such as "anticipate," "believe," "could," "estimate," "expect," "goal," "intend," "look forward to", "may," "plan," "potential," "predict," "project," "should," "will," "would" and similar expressions. Forward-looking statements appear in a number of places throughout this release and include statements regarding our intentions, beliefs, projections, outlook, analyses and current expectations concerning, among other things, our ongoing and planned preclinical development and clinical trials, our collaborations and development of our products in combination with other therapies, the timing of and our ability to make regulatory filings and obtain and maintain regulatory approvals for our product candidates our intellectual property position, our collaboration activities, our ability to develop commercial functions, expectations regarding clinical trial data, our results of operations, cash needs, financial condition, liquidity, prospects, future transactions, growth and strategies, the industry in which we operate, the trends that may affect the industry or us and the risks uncertainties and other factors described under the heading “Risk Factors” in Affimed’s filings with the Securities and Exchange Commission. Given these risks, uncertainties and other factors, you should not place undue reliance on these forward-looking statements, and we assume no obligation to update these forward-looking statements, even if new information becomes available in the future.

Affimed IR Contact

Caroline Stewart, Head IR
Phone: +1 347 394 6793
E-Mail: email hidden; JavaScript is required or email hidden; JavaScript is required

Media Requests

Stephanie May or Gretchen Schweitzer
MacDougall Biomedical Communications
Phone: +49 89 2424 3494 or +49 172 861 8540
E-Mail: email hidden; JavaScript is required